Stocktoria
AYTU BIOPHARMA, INC AYTU
AYTU BIOPHARMA, INC (AYTU) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $66.4M at a -20.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.67 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.13 |
| Retained earnings / assets | -2.686 |
| EBIT / assets | -0.063 |
| Equity / liabilities | 0.18 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AYTU | AYTU BIOPHARMA, INC | 4/9 | -8.14 | — | +1.8% |
| SPRO | Spero Therapeutics, Inc. | 4/9 | -8.9 | 15.3 | +39.2% |
| ENTA | ENANTA PHARMACEUTICALS INC | 4/9 | -2.79 | — | -3.4% |
| KURA | Kura Oncology, Inc. | 2/9 | -2.37 | — | +25.2% |
| RMTI | ROCKWELL MEDICAL, INC. | 2/9 | -18.33 | — | -31.8% |
| FBIO | Fortress Biotech, Inc. | 4/9 | -12.29 | 13.5 | +9.7% |
| NUVB | Nuvation Bio Inc. | 3/9 | -2.01 | — | — |
About AYTU BIOPHARMA, INC
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
FAQ
Is AYTU financially healthy?
AYTU BIOPHARMA, INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does AYTU pay a dividend?
No, AYTU BIOPHARMA, INC does not currently pay a dividend.
How profitable is AYTU?
In FY2025, AYTU BIOPHARMA, INC had a net margin of -20.4% and a return on equity of -71.5%.
What is the analyst price target for AYTU?
The average Wall-Street price target for AYTU BIOPHARMA, INC is $9.50, about 302.5% above the recent price, from 3 analysts.
Is AYTU a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AYTU BIOPHARMA, INC: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.